The investigators propose that the skin, because of its high UV-mutagenic burden, can serve as a discovery platform for inherited cancer predisposition variants. The concept is that recurrent or extreme cutaneous mutational signal—manifested clinically as frequent skin cancers—may unmask underlying germline susceptibilities that also increase risk for internal malignancies.
The study reported here focuses on patients with a high frequency of basal cell carcinoma (hfBCC) to test this approach. The source frames skin mutagenesis as a tractable tissue in which somatic and germline signals may converge to reveal candidate predisposition genes.
In the reported cohort, patients defined as having hfBCC demonstrated a higher prevalence of internal cancers. Specifically, the authors state that hfBCC patients had a three-fold higher internal malignancy prevalence. The abstract does not specify the absolute rates, comparator group, cohort size, or detailed cancer types beyond the examples noted with genetic findings; those specifics were not reported in the provided source material.
The observed association between frequent cutaneous neoplasia and greater internal malignancy burden underpins the strategy of interrogating skin-driven mutational patterns to detect germline cancer-susceptibility variants.
Using the hfBCC-focused approach, the study identified a novel candidate mutation in EPHB2 that the authors associate with both basal cell carcinoma and prostate cancer in their dataset. The source characterizes this variant as a candidate cancer susceptibility mutation rather than a definitively validated pathogenic germline allele.
The abstract does not provide variant coordinates, allele frequency data, segregation analyses, functional validation, statistical metrics, or replication cohort results. Therefore, additional methodological and evidentiary details are not available from the provided text and would require consulting the full preprint or subsequent peer-reviewed publication.
The authors interpret their results as demonstrating the potential of the skin to act as a powerful platform for discovery of inherited cancer predisposition variants. Because skin is frequently exposed to mutagenic UV radiation and develops observable clonal lesions, it may offer a window into both somatic mutation landscapes and underlying germline risk.
This approach could complement other strategies to identify predisposition genes, particularly when traditional family-based or population-based discovery is challenging. The identification of an EPHB2 candidate variant linked to both cutaneous and internal tumors exemplifies the cross-tissue relevance that motivated the study.
The research received ethical approval from the Institutional Review Board of Stanford University (IRB protocol 36263). The authors confirm that participant consent and relevant reporting guidelines were followed. They declared no competing interests.
Data sharing: the authors state that all data produced in the study will be deposited in the NIH Sequence Read Archive upon peer-review publication. The preprint was posted on medRxiv on October 06, 2026.
Funding for the work was declared from multiple sources, including the Damon Runyon Cancer Research Foundation, the National Cancer Institute (K23 CA211793), the American Skin Association, the Howard Hughes Medical Institute, the Dermatology Foundation, and the Chan Zuckerberg Biohub San Francisco.
The provided source text is an abstract-level summary from a medRxiv preprint and omits many technical and quantitative details. The following items were not reported in the provided material and therefore cannot be asserted here:
Those methodological and evidentiary elements will be necessary to evaluate the robustness of the reported three-fold internal malignancy prevalence and the candidacy of the EPHB2 mutation; they may be available in the full preprint or following peer-reviewed publication.
The report presents a strategy that uses the skin’s high UV-driven mutational load to interrogate patients with frequent basal cell carcinomas for inherited cancer predisposition variants. In this preprint, hfBCC patients had a reported three-fold higher prevalence of internal malignancy, and a novel candidate EPHB2 mutation was associated with BCC and prostate cancer. Ethical approval, planned data deposition to the NIH Sequence Read Archive, funding sources, and absence of declared competing interests are noted. Detailed methods and variant-level evidence were not included in the abstract and would be needed to fully appraise these findings.